Pascal Dauphin, MD
Endocrinology, Diabetes & Metabolism · Hendersonville, TNNPI 1154324325
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $708,665 of the $924,785 with a category attached, or 76.6%. 58 manufacturers reported payments, led by Lilly USA, LLC at 47.7% of the total. Reporting peaked in 2019 at $287,086 and has fallen 53.2% since, to $134,218 in 2025. Among endocrinology, diabetes & metabolism clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,200 payments — averaging $420.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$441K
- Amgen$181K
- AstraZeneca$74K
- Radius Health, Inc.$40K
- Merck$39K
- Sanofi-aventis U.S. LLC$25K
- plus $123K from 52 others
What the payments were for
- Consulting fees$18,0852%
- Speaking & faculty fees$708,66577%
- Travel & lodging$158,84317%
- Food & beverage$38,9164%
- Education$2770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$924,785 in reported general payments places this provider in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 375 | $437,520 |
| TrulicityDulaglutide | 318 | $385,016 |
| MounjaroTirzepatide | 237 | $266,517 |
| JardianceEmpagliflozin | 165 | $172,658 |
| FarxigaDapagliflozin Propanediol | 170 | $142,281 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 155 | $107,363 |
| Tresiba Flextouch U-200Insulin Degludec | 108 | $93,323 |
| Tresiba Flextouch U-100Insulin Degludec | 130 | $90,371 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $78,230 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 47 | $59,607 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 59 | $54,200 |
| Xigduo XrDapaglifloz Propaned/Metformin | 63 | $45,743 |
| JanuviaSitagliptin Phosphate | 46 | $37,490 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $33,709 |
| Teriparatide | 15 | $31,532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $441,150 | $658,589580 claims |
| Novo NordiskOzempic, Novolog | $14,025 | $450,208417 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $711 | $245,228251 claims |
| AstraZenecaFarxiga | $74,473 | $142,281170 claims |
| MerckJanuvia, Janumet Xr | $39,108 | $53,81476 claims |
| AbbVieSynthroid | $349 | $9,860133 claims |
| BayerKerendia | $22,000 | $7,70712 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $78 | $6,388795 claims |
| Sanofi-aventis U.S. LLCLantus | $25,445 | $5,33633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Hendersonville
- Alan CohenMemphis$1.4M
- Craig WierumNashville$1.3M
- Shimon HararyMemphis$735K
- Lisa MyersGermantown$609K
- Amit VoraKnoxville$579K
- Terri JerkinsNashville$567K
- Samuel Dagogo-JackMemphis$407K
- Michael CarlsonNashville$381K
- David EscalanteJellico$326K
- Kathryn DahirNashville$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.